Precise underwater navigation is critical for autonomous and remotely operated deep-sea vehicles, yet variations in seawater ...

Exagen Inc. (NASDAQ:XGN) Q3 2025 Earnings Call Transcript November 4, 2025 Exagen Inc. misses on earnings expectations. Reported EPS is $-0.19 EPS, expectations were $-0.13. Operator: " Ryan Douglas: ...

Delivered record total revenue of $17.2 million, representing a 38% increase compared to the third quarter of 2024, or a 26% increase before the impact of one-time adjustments recorded in 2024. Grew ...

Grew AVISE CTD test volume 16% compared to the third quarter of 2024. Expanded AVISE CTD trailing twelve-month ASP to $441 per test, an increase of $37 per test over the third quarter of 2024. Ended ...

Revenue: $17.2 million in Q3, highest quarter in history, nearly 40% increase over Q3 2024. Year-to-Date Revenue: Approximately $50 million, 19% growth through Q3. Gross Margin: Just over 58% in Q3, ...

Delivered record total revenue of $17.2 million, which represents 11% growth compared to the first quarter of 2025 and 14% growth compared to the second quarter of 2024. Grew AVISE CTD test volume 14% ...

- Revenue (GAAP) rose to $17.2 million, surpassing analyst expectations by 5.5% and grew 14.2% year over year. - AVISE CTD test volume increased 14% sequentially, and the trailing-twelve-month average ...

NEW YORK – Investment bank Craig-Hallum said Wednesday that it has initiated coverage of autoimmune testing firm Exagen with a Buy rating and a $12 price target. Analyst Bill Bonello said in a note to ...

Delivered record total revenue of $15.5 million on the strength of continued ASP expansion and AVISE CTD test volume growth. Expanded AVISE CTD trailing twelve-month ASP to $419, an increase of $42 ...